TriangleNCT04421027 · OUTCOME
Time to Recovery
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Day 1 to Day 28
What was measured
Recovery assessed by the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS). Time to reach NIAID-OS 1, 2, or 3 for the first time. The date reached is the first full day that OS 1, 2, or 3 is the participant's maximum OS for the day. NIAID-OS 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities and/or requiring home oxygen 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.)
Analysis population: All participants randomly assigned to study intervention.
Groups in this outcome
Placebo + SOC
Placebo administered orally QD with standard of care.
Baricitinib + SOC
4 mg baricitinib administered orally QD with standard of care.
| Group | Source count |
|---|---|
| Placebo + SOC | 761 |
| Baricitinib + SOC | 764 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Placebo + SOC | 11.0 | Not reported | 10.0 | 12.0 | Not reported |
| Baricitinib + SOC | 10.0 | Not reported | 9.0 | 11.0 | Not reported |
Source statistical analyses
- ci Lower Limit
- 0.99
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.24
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.1453
- param Type
- Hazard Ratio (HR)
- param Value
- 1.11
- statistical Method
- Log Rank
Complete source fields
- analyses
- ci Lower Limit
- 0.99
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.24
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.1453
- param Type
- Hazard Ratio (HR)
- param Value
- 1.11
- statistical Method
- Log Rank
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 10.0
- upper Limit
- 12.0
- value
- 11.0
- group Id
- OG001
- lower Limit
- 9.0
- upper Limit
- 11.0
- value
- 10.0
- denoms
- counts
- group Id
- OG000
- value
- 761
- group Id
- OG001
- value
- 764
- units
- Participants
- description
- Recovery assessed by the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS). Time to reach NIAID-OS 1, 2, or 3 for the first time. The date reached is the first full day that OS 1, 2, or 3 is the participant's maximum OS for the day. NIAID-OS 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities and/or requiring home oxygen 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.)
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Placebo administered orally QD with standard of care.
- id
- OG000
- title
- Placebo + SOC
- description
- 4 mg baricitinib administered orally QD with standard of care.
- id
- OG001
- title
- Baricitinib + SOC
- param Type
- MEDIAN
- population Description
- All participants randomly assigned to study intervention.
- reporting Status
- POSTED
- time Frame
- Day 1 to Day 28
- title
- Time to Recovery
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice